When did Xifaxan’s original patents expire?
The main US patent that covers the rifaximin molecule, U.S. Patent 5,456,284, was issued in 1997 and expired in 2005. That patent is long expired and no longer protects the drug’s core chemistry.
What other patents keep Xifaxan on the market?
Pfizer has filed several later patents on formulation, delivery, and manufacturing processes. According to DrugPatentWatch, these patents expire in 2027–2028, which keeps the brand exclusive in the United States for the foreseeable future.
Will a generic version appear soon?
Because the latest patents are still in force, a generic can only be approved after their expiry, likely in 2028. Even then, the FDA must grant generic approval, which could add a year or two.
Does FDA exclusivity still apply?
Xifaxan received a 5‑year New‑Drug Application exclusivity period (2003–2008) and a 5‑year data exclusivity (2003–2008). Those exclusivities ended long ago; they do not affect current patent protection.
Why hasn’t a generic been launched yet?
The remaining patents give Pfizer a legal advantage. A generic applicant would need to design around them or wait until the expiration dates pass.
What about international patents?
Patents outside the U.S. vary. In the EU, rifaximin patents expire around 2029–2030, so generics there could appear later than in the U.S.
How do these dates affect pricing and insurance?
Because no generic exists, the price remains set by Pfizer. Insurance formularies typically cover Xifaxan at the brand price, which keeps the drug costly.
When can patients expect lower costs?
Once the 2027–2028 patents lapse and a generic is approved, competition should drive prices down, and insurers may negotiate lower rates.
Are there any regulatory hurdles left?
The only potential barriers are the remaining patents and the FDA’s approval process for generics. Once those clear, the drug could enter generic competition.
Can biosimilars or alternative antibiotics compete now?
No biosimilar exists because rifaximin is a small‑molecule antibiotic, not a biologic. Alternative antibiotics are already on the market and can be used where Xifaxan is indicated, but they are not generic Xifaxan.
How long will the drug stay patent‑protected?
Current data show the last active patents expire in 2028. After that, the drug enters the generic phase unless new patents are filed.
Key takeaway for patients and providers
Xifaxan’s core chemistry patent is long expired, but newer formulation and process patents keep the drug exclusive until 2028. A generic is expected after that, which should reduce costs.
Sources
[1] https://www.drugpatentwatch.com/patents/16525